In a nation where we are taught to believe the NHS is a sacred institution built on compassion, equality, and ethical care, the stark reality unveiled by recent documents from the PARAMEDIC-3 trial shatters that illusion. Behind the blue lights and emergency sirens lies a chilling truth: the British public has become nothing more than data points in a financial model and, more disturbingly, potential sources of organ revenue.
The PARAMEDIC-3 trial, coordinated by Warwick University’s Clinical Trials Unit, was not a study focused on improving survival outcomes. It was, by its own admission, a cost-effectiveness trial testing whether intraosseous (IO) administration of adrenaline (epinephrine) could be economically preferable to intravenous (IV) access during cardiac arrest events [1].
But that is only the surface of the horror.
Cheaper Deaths and More Organs: A Grim Equation
The trial protocol explicitly states that researchers would be constructing decision-analytic models to evaluate “the long-term cost-effectiveness of IO access first strategy vs IV access” [1]. It continues:
“We will also explore the impact of organ recovery on the cost-effectiveness analysis” [1].
Let that sink in.
Organ recovery an outcome that necessitates death was not only considered a variable, it was factored into the financial modelling of emergency response strategies. This means that if a patient died but their organs were harvested, that may be counted as a beneficial economic outcome.
Is this medical care or human commodification?
IO Access: A Known Risk for Worse Outcomes
The use of intraosseous adrenaline injected directly into the bone is not new, but its selection as a first-line strategy is deeply controversial. Research, including findings from the original PARAMEDIC-2 trial, demonstrated that adrenaline may restore a heartbeat but at a devastating neurological cost, often leaving patients brain-damaged or never regaining consciousness [2].
A 2020 systematic review reinforced this, showing that intraosseous access in cardiac arrest is associated with significantly lower survival and poorer neurological outcomes compared to intravenous access [3]. Yet this high-risk route was rolled out in the PARAMEDIC-3 study, not for medical necessity, but to assess which option saved more money.
If you collapsed in East Sussex or elsewhere during the trial period, you may have been randomised into a treatment arm that gave you a known inferior intervention without your knowledge or consent.
Adrenaline: Restarting Hearts, Destroying Brains
Even when not delivered via IO, adrenaline’s safety has long been in question. The PARAMEDIC-2 trial (2018) concluded that while it increased survival to hospital admission, it did not improve neurological outcomes, and most survivors had severe brain damage [2].
Another major study published in 2020 found that adrenaline has complex, potentially harmful impacts on the brain and other organs, and called for further research into its long-term consequences [4].
So why is adrenaline still the frontline treatment especially when delivered by high-risk IO access in experimental trials? The answer, it seems, lies not in care, but in commerce.
Consent Violations: A Nation Enrolled Without Knowledge
The PARAMEDIC-3 protocol confirms the use of a waiver of consent in emergency scenarios [1]. In other words, you could be enrolled in a trial that determines your fate the moment a 999 call is placed without your family knowing, without your rights being read, and without any possibility of opting out.
This is not just unethical; it is a violation of international law. The Nuremberg Code and the Declaration of Helsinki require full, voluntary, and informed consent for any human experimentation. Emergency medicine does not override human rights.
The Ultimate Conflict of Interest: Your Body as a Revenue Source
The most disturbing revelation in the PARAMEDIC-3 protocol is that organ recovery was included in economic modeling. This alone should trigger national outrage.
It implies that death is economically incentivised especially if a patient’s organs can be harvested. The NHS already operates under protocols where donation after brainstem death is streamlined, often without family understanding the full implications. The “death” declared is not always total death. In many cases, brain activity is still present yet ventilation is withdrawn, often quickly and without independent review.
When this is coupled with a resuscitation model designed not to save life, but to minimise cost and maximise resource retrieval, the line between care and killing becomes dangerously thin.
Conclusion: This Is Not Healthcare, It Is Bio economic Exploitation
The British public must wake up. We are no longer patients. We are assets on a balance sheet. Our veins are conduits for experimentation. Our bones are access points for chemical interventions. And when we are no longer responsive, our hearts, livers, lungs, and kidneys are extracted like parts from a used machine, tallied in spreadsheets under “organ recovery”.
This is not conspiracy, it is openly declared in peer-reviewed protocols and trial documents [1][2][3].
Gavin Perkins, lead investigator and head of Warwick’s trial unit, should face criminal prosecution. The same applies to any clinician or institution that permitted this study without proper public disclosure and independent oversight. The UK’s emergency protocols must be scrutinised, and all cost-based triage models linked to organ harvesting must be outlawed immediately.
Let this article be a formal warning and a public call to action. Because if we remain silent, we are next.
References
[1] PARAMEDIC-3 Trial Protocol, Version 1.0 (10 November 2023), Warwick Clinical Trials Unit. https://warwick.ac.uk/fac/sci/med/research/ctu/trials/paramedic3/analysis/paramedic-3_heap_v1.0_10nov2023.pdf
[2] Perkins, G.D., et al. (2018). A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. New England Journal of Medicine, 379:711–721. https://pubmed.ncbi.nlm.nih.gov/30021076/
[3] Rees, N. et al. (2020). Neurological outcomes after intraosseous vs intravenous access in out-of-hospital cardiac arrest: A systematic review and meta-analysis. Resuscitation, 149: 132–138.
[4] Olasveengen, T.M. & Semeraro, F. (2020). Adrenaline in Cardiac Arrest: More Questions Than Answers. Resuscitation, 156: 280–281. https://pubmed.ncbi.nlm.nih.gov/32981529/
Article posted with permission from Kate Shemirani
